Uncategorized
Physicians, industry, investors convene for the Ophthalmology Innovation Summit, part 2
CHICAGO – Ocular Surgery News has captured the substance and spirit of the remarks made by the speakers here at the Ophthalmology Innovation Summit’s Device, Delivery and Diagnostic Company Showcase. Tim Willis, TearScience co-founder and CEO, discussed the company’s U.S. Food and Drug Administration-cleared product to identify, diagnose and treat meibomian gland dysfunction.